

IHI Call Days | Call 12

Unravelling mechanism-of-action for improved disease management of disabling neurological conditions including migraine and cluster headache

Wim Pollet (Chief Medical Officer, Salvia BioElectronics)

Contact: Daniel Schobben

Organisation: Salvia BioElectronics BV

E-mail: daniel.schobben@salvianeuro.com

Links on the IHI brokerage platform:

- [Proposal sharing tool](#)
- [Salvia BioElectronics](#)



Challenges and objectives

Problem: the lack of understanding in chronic disease leads to late diagnosis and a long journey to identify effective therapies for the individual patient.

IHI specific objective: “Contribute towards a better understanding of the determinants of health and priority disease areas” (SO1).

Unmet public health addressed: migraine and cluster headache.





Your approach to solve the problem

- MedTech, Pharma and Academic hospitals team up to make effective therapies widely accessible.
- Disease will be correlated with objective biomarkers to enable responder identification and therapy optimization.





Is your project suitable for IHI?

- Large-scale public-private collaboration is key to develop models and recognition of phenotypes associated with clinical outcomes to reduce prolonged trial-and-error treatment cycles, prevent chronification and optimize healthcare expenditure.
- Migraine and cluster headache patients typically use several complementary therapies. Therapies where previously mostly limited to pharm, and now also MedTech solutions are emerging.
- With the growing number of treatment options, a more efficient method is needed for effective treatment referral



Outcomes and Impact

- Results/outcomes impact: objective biomarkers and predictors for response.
- Impact: earlier diagnosis and referral for effective therapies.
- Translation from research to innovative solutions: academic hospitals bring in prior research.
- Strengthening European competitiveness: participating European industry can leapfrog to a leading position based on deep insights in disease management.
- Expected benefits for patients: by placing the patient first, MedTech and pharma build on their complementary strengths to make effective care broadly available to those in medical need.



Expertise and resources

The consortium is newly established.

- We are looking for:
 - Pharma companies with an interest in migraine and/or cluster headache
 - Academic hospitals with previous research on mechanism-of-action research

We are providing in-kind contributions (IKOP and IKAA).